Five things for pharma marketers to know: Tuesday, January 3, 2017

Photo credit: e-Magine Art/Creative Commons

1. The FDA approved 22 new drugs in 2016, the lowest number since 2010. Experts said the approval rate is nearing normal levels after spikes in 2014 and 2015. (Reuters)

2. The Philippines' Food and Drug Administration has ordered Sanofi to stop airing ads for Dengvaxia, its dengue-fever vaccine. The regulator said the drugmaker is violating a ban on promoting prescription drugs in the media. (AP)

3. Biogen's Spinraza, the newly approved treatment for spinal muscular atrophy, is expected to have a list price of $125,000 for one dose. A full year of treatment will cost $375,000. (NYT)

4. About half of the published clinical studies examining new medical treatments leave out some adverse events reported during the trial, a new study found. (Scientific American)

5. Researchers who looked at the 62 cancer drugs approved in the U.S. and Europe between 2003 and 2013 found that the therapies extended survival by an average of 3.5 months. Additionally, a third of those drugs failed to demonstrate that they increased survival when compared to other treatments. (Reuters)